| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | AZD-7545 | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | 0.0075 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |